|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Memorial Sloan-Kettering Cancer Center |
|---|---|
| Collaborators: |
Rockefeller University Flinders Medical Centre Aureon Biosciences, Inc. University of Southern California Gen-Probe, Incorporated Genentech General Electric Purdue University Biocept, Inc. Duke University Ikonysis, New Haven, CT Array Genomics Cold Spring Harbor Laboratory |
| Information provided by (Responsible Party): | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00578240 |
Purpose
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
| Condition |
|---|
|
Prostate Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Molecular Studies and Clinical Correlations in Human Prostatic Disease |
Human tissue, body fluids, and blood
| Estimated Enrollment: | 2500 |
| Study Start Date: | April 1990 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
Eligibility| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Primary care clinic
Inclusion Criteria:
Men with prostate conditions representing the following disease states:
Exclusion Criteria:
Contacts and Locations| Contact: Susan Slovin, MD | 646-422-4470 | |
| Contact: James Eastham, MD | 646-422-4390 |
| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Principal Investigator: | Susan Slovin, MD | Memorial Sloan-Kettering Cancer Center |
More Information
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00578240 History of Changes |
| Other Study ID Numbers: | 90-040 |
| Study First Received: | December 19, 2007 |
| Last Updated: | December 15, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
benign Rising PSA Clinical Metastases 90-040 |
|
Prostatic Diseases Prostatic Neoplasms Genital Diseases, Male Genital Neoplasms, Male |
Urogenital Neoplasms Neoplasms by Site Neoplasms |
